Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in ICVTS w1x.
Clinical scenario
You are the cardiac surgeon on call. A 55-year-old male patient comes to the emergency department. He has fever, tiredness and dyspnea for the previous few days. On examination, you hear a diastolic heart murmur in the aortic valve area. The patient appears hemodynamically unstable. Transthoracic echocardiography shows severe aortic valve incompetence with vegetations and a suspected abscess. You diagnose active aortic endocarditis and alert the surgical team. Your resident wonders whether or not a stentless prosthesis would have the same outcome as a homograft and which is the best solution for the patient. You resolve to check the literature for evidence. *Corresponding author. Tel.: q46 737 238120; fax: q46 031 417991. E-mail address: perrottasossio@yahoo.com (S. Perrotta).
Three-part question
In wpatients with severe active aortic valve endocarditisx is wa stentless valvex as good as a whomograftx for wlong term event free survivalx?
Search strategy
Medline search 1950-December 2009 was performed using the OVID interface.
wexp *BioprosthesisyOR stentless prosthesis.mp. OR *Treatment OutcomeyOR aortic homograft.mp.x AND w*EndocarditisyOR aortic valve endocarditis.mp. OR active infective endocarditis.mp.x.
The 'related article' function was used to broaden the search and all the abstracts, studies, and citations scanned were reviewed.
Search outcome
One hundred and eight papers were found using the reported search. Twelve are included in this article and 10 Downloaded from https://academic.oup.com/icvts/article-abstract/11/3/309/814610 by guest on 06 March 2019 SP, stentless prosthesis; AIE, active infective endocarditis; NAV, native aortic valve; PAV, prosthetic aortic valve; AH, aortic homograft; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; EF, ejection fraction; NVE, native valve endocarditis; PVE, prosthesis valve endocarditis; AVR, aortic valve replacement; ARR, aortic root replacement; SIMVD, secondary infective mitral valve disease; AVSP, aortic valve stentless prosthesis; MVSP, mitral valve stentless prosthesis; MVRec, mitral valve reconstruction; AVP, aortic valve prosthesis; MVP, mitral valve prosthesis. papers represent the best evidence topic on the subject (Table 1) .
Discussion
Many authors consider the aortic homograft the gold standard for the treatment of aortic valve endocarditis. The following authors w2-5x reported their results with AH in this clinical scenario. In these series with AH, the reinfection rate is low, ranging from 3.8% to 6.8%. In particular, Yankah et al. w2x reported 91% freedom from reinfection at 10 and 17 years, and 70% survival at the 17-year follow-up. Niwaya et al. w3x reported only one case of reinfection (after one year) for 46 patients treated with AH, and a 30-day mortality of 17%. Sabik et al. w4x , in a series of 103 consecutive patients with prosthetic valve endocarditis (PVE) treated with homografts, reported a reinfection rate of 3.8%, freedom from reinfection at 10 years of 95%, and 56% survival at 10 years. Grinda, in his series of 104 patients, reported a reinfection rate of 5.7% and a freedom from reinfection at 10 years of 93%. The low reinfection rate is considered to be the result of both the use of the homograft and the radical debridement of the abscess cavity.
However, AH is not always easily available, and a SP has been used by some authors in this clinical scenario. Musci et al. w6x, in 2008 , published the largest series of Dacron free SP implanted in 255 patients with aortic endocarditis. He reported an overall reinfection rate of 8.6% with freedom from reinfection at five years of 83% and five-year survival of 46%. Furthermore, he did not find a significant difference between survival and freedom from reinfection in patients with native valve endocarditis (NVE) compared to those with PVE (Ps0. 1371 and Ps0.8356) . He reported a difference in survival rate between patients who were operated on urgently, versus in an emergency (P-0.0001), between patients with and without abscess formation (Ps0.0245), and between single and double valve replacements (Ps0.0206). The same authors w7x, in 2010, in a series of 221 patients treated with AH, reported a reinfection rate of 5.4% and 10-year freedom from reoperation and reinfection in native and PVE of 92%. Long-term survival, at 10 years, was better in native that in PVE (Ps0.029).
Siniawski et al. w8x, comparing two groups of patients, one treated with a Dacron free SP and the other with AH, found an equal reinfection rate of 4% and lower mortality for the patients treated with a stentless valve (12% vs. 16%). The same author in 2005 w9x, analyzing a group of 53 patients with aortic and mitral endocarditis, reported 26.4% mortality for double valve surgery, and a reinfection rate of 9.4%. He divided the study group in three subgroups: the first in which the patients have SP on both valves; in the second a homograft is inserted in an aortic position with a standard prosthesis on the mitral valve and the third in which a standard prosthesis is inserted on both valves. He found that the reinfection rate is lower for the homograft and SP compared to that after aortic valve replacement (AVR) using standard prostheses, respectively, 5.8%, 3.7% and 33%. In both articles w8, 9x, the author reported that the use of SP gives good postoperative echocardiographic data, similar to that achieved when cryopreserved homografts are used.
Santini et al. w10x in his series of nine patients treated with SP reported no episode of recurrent endocarditis and concluded that the versatility of the implanted SP appears to be a valuable additional tool when active aortic valve infection is complicated by extensive destruction of contiguous tissue and a homograft is not available.
Müller et al. w11x treated 10 patients with a Freestyle SP. He reported freedom from endocarditis recurrence, early mortality and late mortality, respectively, on two patients and one patient.
Clinical bottom line
The SP offers low reinfection rates ranging from 3.7% to 8.6%. The low reinfection rate and the good hemodynamic values are comparable to cryopreserved homografts. The required SP is available at any time. The design of certain stentless prostheses allows application of a variety of surgical techniques. In patients with less extensive aortic root abscess an SP valve can be implanted in a subcoronary position. For patients with a more extensive infection, where the abscess is localized at and above the level of the annulus, the bioprosthesis can be inserted as a total root replacement. SP implantation via ministernotomy is not widely used w12x. Further follow-up is required to determine stentless valve durability and long-term freedom from valve-related complications.
